X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.globenewswire.com//news-release/2024/02/29/2837979/23024/en/Intercept-Announces-FDA-Acceptance-of-Supplemental-New-Drug-Application-for-Ocaliva-obeticholic-acid-for-the-Treatment-of-PBC.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214899
https://www.fiercepharma.com/pharma/after-two-fda-rejections-and-restructuring-plan-intercept-agrees-alfasigma-buyout
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214935
https://www.fiercepharma.com/pharma/intercepts-nash-hopes-dashed-fda-throws-ocaliva-app-trash-can-after-harsh-review
https://www.globenewswire.com/news-release/2023/06/22/2693358/23024/en/Intercept-Receives-Complete-Response-Letter-from-FDA-for-Obeticholic-Acid-as-a-Treatment-for-Pre-Cirrhotic-Fibrosis-due-to-NASH.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214862
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215017
https://www.fiercebiotech.com/medtech/paradromics-reels-33m-fda-breakthrough-tag-mind-reading-brain-implant
https://www.globenewswire.com/news-release/2023/03/10/2624989/23024/en/Intercept-Announces-FDA-Advisory-Committee-Meeting-Date-for-Obeticholic-Acid-as-a-Treatment-for-Pre-Cirrhotic-Liver-Fibrosis-due-to-NASH.html
https://www.globenewswire.com//news-release/2022/12/23/2579114/23024/en/Intercept-Resubmits-New-Drug-Application-to-U-S-FDA-for-Obeticholic-Acid-in-Patients-with-Liver-Fibrosis-due-to-NASH.html
https://www.globenewswire.com//news-release/2022/12/08/2570728/23024/en/New-Study-Published-in-The-American-Journal-of-Pathology-Suggests-Obeticholic-Acid-OCA-May-Improve-Cognitive-Impairment-Associated-with-Cholestatic-Liver-Disease.html
https://www.globenewswire.com/news-release/2022/09/20/2519590/23024/en/Improved-Transplant-Free-Survival-Observed-with-Obeticholic-Acid-in-People-with-PBC-Published-in-Gastroenterology.html
https://www.globenewswire.com/news-release/2022/07/07/2475765/23024/en/Intercept-Announces-Positive-Data-in-Fibrosis-due-to-NASH-from-a-New-Analysis-of-its-Phase-3-REGENERATE-Study-of-Obeticholic-Acid-OCA.html
https://www.globenewswire.com/news-release/2022/05/05/2436641/23024/en/Intercept-Announces-Advanz-Pharma-to-Acquire-Ocaliva-in-PBC-in-Markets-Outside-the-U-S-for-up-to-450MM-including-405MM-Upfront-and-an-Additional-45MM-in-Contingent-Payments.html
https://www.biopharmadive.com/news/intercept-withdraw-nash-drug-europe/611253/
https://pharmaphorum.com/news/intercepts-travails-continue-as-it-pulls-nash-drug-filing-in-eu/
https://www.globenewswire.com/news-release/2021/11/15/2334225/23024/en/Intercept-Announces-New-Long-Term-Data-Demonstrating-Potential-of-Obeticholic-Acid-to-Improve-Transplant-Free-Survival-in-Patients-with-PBC.html
https://finance.yahoo.com/news/intercept-announces-long-term-data-130000857.html
https://amilifesciences.com/left_service/ami-lifesciences-first-generic-company-to-receive-dcgi-approval-for-obeticholic-acid/
https://www.biopharmadive.com/news/intercept-ocaliva-fda-warning-label-liver-injury/600939/
https://www.medscape.com/viewarticle/951931#:~:text=FDA%20Restricts%20Obeticholic%20Acid%20(Ocaliva)%20Over%20Serious%20Liver%20Injury%20Risk&text=The%20risk%20for%20serious%20liver,(PBC)%20and%20advanced%20cirrhosis.
https://endpts.com/in-another-blow-to-intercept-the-fda-investigates-ocaliva-for-potential-risk-of-liver-disorder/
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-ocaliva-207999-obeticholic-acid-tablets-5-mg-and-10-mg-1594796248.pdf
https://pink.pharmaintelligence.informa.com/PS142469/Intercept-CRL-Likely-About-OCASpecific-Concerns-Not-NASH-Endpoints
https://www.biopharmadive.com/news/nash-obeticholic-acid-ocaliva-fda-delay-intercept/578518/
https://www.fiercepharma.com/pharma/after-earlier-fda-delay-intercept-s-nash-hearing-pushed-back-due-to-covid-19
https://endpts.com/covid-19-roundup-biopharma-industry-teams-up-to-spur-defensive-arsenal-to-fight-pandemic-regeneron-relaxes-eylea-payment-terms/
https://www.biopharmadive.com/news/2-nash-drugmakers-have-wildly-different-mondays/567990/
https://www.fiercepharma.com/pharma/aasld-intercept-ocaliva-data
https://endpts.com/genfit-goes-to-china-with-a-deal-worth-up-to-228m-for-nash-drug/
https://www.fiercebiotech.com/research/ada-ngm-backs-up-case-for-once-monthly-dosing-merck-partnered-nash-drug
https://www.fiercepharma.com/pharma/intercept-turns-to-subgroup-analysis-for-nash-hopeful-ocaliva-will-safety-still-be-a-thorn
https://www.fiercepharma.com/pharma/intercept-turns-to-subgroup-analysis-for-nash-hopeful-ocaliva-will-safety-still-be-a-thorn
https://endpts.com/while-we-wait-for-nash-data-genfit-reports-positive-elafibranor-data-in-pbc-patients/
https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12146818/intercept-pharma-notches-2-upgrades-on-ocaliva-prospect
http://ir.interceptpharma.com/news-releases/news-release-details/liver-biopsy-data-poise-phase-3-substudy-supports-obeticholic
http://ir.interceptpharma.com/news-releases/news-release-details/intercept-announces-multiple-new-ocalivar-obeticholic-acid-data
http://ir.interceptpharma.com/news-releases/news-release-details/intercept-announces-updated-us-prescribing-information-ocalivar
http://timesofindia.indiatimes.com/business/international-business/novartis-has-assets-to-sell-investors-wary-of-what-it-might-buy/articleshow/58908544.cms
http://www.pharmatimes.com/news/ocalvia_gets_nhs_green_light_for_rare_chronic_liver_disease_1191983
http://www.pharmatimes.com/news/nice_backs_new_treatment_for_chronic_liver_disease
http://www.biospace.com/News/why-intercept-pharma-stock-jumped-nearly-10-on/446434/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
http://www.biospace.com/News/novartis-ag-rumored-to-be-buying-intercept-pharma/442875/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
https://globenewswire.com/news-release/2016/12/14/897530/0/en/European-Commission-Grants-Intercept-s-Ocaliva-obeticholic-acid-Marketing-Authorization-for-the-Treatment-of-Primary-Biliary-Cholangitis.html
http://www.fool.com/investing/2016/11/16/3-potential-acquisition-targets-for-gilead-science.aspx?
Market Place
Share 
